Opus Genetics IRD
NASDAQ IRD
$4.67 +0.07 (+1.52%)
As of: Sep 4, 2026 · 3:59 PM EDT

Opus Genetics (IRD) FCF Margin Growth (1y) (2023 - 2026)

Analysis

Opus Genetics (IRD) FCF Margin Growth (1y) (2023 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -89.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1,183.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 26,102.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 869.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 769.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - 811.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 19,111.00
10 Opus Genetics 446.86 Mn 358.05 Mn - -122,647.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -122,647.00
Mar 31, 2026 -38,422.00
Dec 31, 2025 -8,152.00
Sep 30, 2025 -6,731.00
Jun 30, 2025 29,944.00
Mar 31, 2025 12,826.00
Dec 31, 2024 -44,185.00
Sep 30, 2024 -10,750.00
Jun 30, 2024 -68,267.00
Mar 31, 2024 -12,561.00
Dec 31, 2023 19,670.00